Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions
CONCLUSION: ERBB2 amplification is frequently encountered among patients with uterine serous carcinoma, and mucinous ovarian carcinoma. In addition, a high incidence was also observed among those with uterine clear cell carcinoma, and uterine carcinosarcoma. For patients with endometrioid endometrial carcinoma, incidence of ERBB2 amplification is low, especially in the absence of TP53 mutations.PMID:38029652 | DOI:10.1016/j.ygyno.2023.11.021
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Dimitrios Nasioudis Stefan Gysler Nawar Latif Lory Cory Robert L Giuntoli Sarah H Kim Fiona Simpkins Lainie Martin Emily M Ko Source Type: research